Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • AML3D announces stronger FY26, with positive EBITDA reported in the second half
    AML3D announces stronger FY26, with positive EBITDA reported in the second half
    • News

  • Refurbished tech gives Harris Technology a second life
    Refurbished tech gives Harris Technology a second life
    • News

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    • News

  • Green360 Secures Holcim as First Commercial Eco-Clay Customer in Major Validation Milestone
    Green360 Secures Holcim as First Commercial Eco-Clay Customer in Major Validation Milestone
    • News

  • Aerometrex Expands MetroMap Partner Program as Scalable Model Gains Traction
    Aerometrex Expands MetroMap Partner Program as Scalable Model Gains Traction
    • News

  • Middle East Conflict Starts to Hurt Corporate Earnings Outlooks
    Middle East Conflict Starts to Hurt Corporate Earnings Outlooks
    • News

  • European Lithium and Critical Metals Secure Control of Tanbreez Rare Earth Project
    European Lithium and Critical Metals Secure Control of Tanbreez Rare Earth Project
    • News

  • Harris Technology’s refurbished boom signals FY26 profit inflection
    Harris Technology’s refurbished boom signals FY26 profit inflection
    • News

Little Green Pharma to supply medicinal cannabis to underserviced German market

  • In News
  • February 27, 2020
  • Conor Murphy
Little Green Pharma to supply medicinal cannabis to underserviced German market

Australian medicinal cannabis and healthcare company Little Green Pharma (ASX: LGP) has this morning announced a key purchase agreement with Berlin-based DEMECAN for the sale and export of up to 1000kg of dried cannabis flower or 48,000 units of medicinal cannabis per annum.

The agreement makes LGP one of the first few companies to export full spectrum medicinal cannabis oil products into the German market, one of the largest such markets in the European Union.

Limited domestic production and cultivation tendering delays has left patients underserviced in the German market, creating a timely opportunity for LGP. 

The Company noted in their announcement that the German medicinal cannabis market is estimated to be worth AU$12.5 billion by 2028, with the number of prescriptions growing rapidly in the last 24 months.

“We are thrilled to enter into a partnership with DEMECAN. As the only company in Germany to cover the entire production chain for medicinal cannabis, DEMECAN is a leading supplier of medicinal cannabis in Germany,” said Little Green Pharma Managing Director Fleta Solomon.

“Germany is home to the largest population in the European Union and a rapidly growing medicinal cannabis industry.”

“The agreement with DEMECAN allows LGP to expand its sales and distribution footprint in Germany to meet the growing demand for medicinal cannabis.”

Little Green Pharma listed on the ASX only a week ago, following an oversubscribed $10 million IPO raise at an issue price of $0.45.

Although now below the IPO issue price, shares in LGP responded well to the announcement, reaching a high of $0.44 in morning trade, a rise of 8.64% on the previous day’s close of $0.405

  • About
  • Latest Posts
Conor Murphy
Conor Murphy is the Marketing Coordinator at TradersCircle
Latest posts by Conor Murphy (see all)
  • Trading the ASX – Get your head around economic data releases - September 5, 2024
  • Cost cutting is all the rage right now - September 5, 2024
  • Novatti’s strategic moves pave the way for positive cash flow amidst $4m in cost reductions - January 31, 2024
  •  
  •  
  •  
  •  
  • asx lgp
  • DEMECAN
  • Fleta Solomon
  • initial public offering
  • IPO
  • lgp
  • Little green pharma
  • medicinal cannabis
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Conor Murphy
Conor Murphy is the Marketing Coordinator at TradersCircle
Latest posts by Conor Murphy (see all)
  • Trading the ASX – Get your head around economic data releases - September 5, 2024
  • Cost cutting is all the rage right now - September 5, 2024
  • Novatti’s strategic moves pave the way for positive cash flow amidst $4m in cost reductions - January 31, 2024

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Conor Murphy
Conor Murphy is the Marketing Coordinator at TradersCircle
Latest posts by Conor Murphy (see all)
  • Trading the ASX – Get your head around economic data releases - September 5, 2024
  • Cost cutting is all the rage right now - September 5, 2024
  • Novatti’s strategic moves pave the way for positive cash flow amidst $4m in cost reductions - January 31, 2024
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.